Truist Financial Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

Truist Financial started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA - Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $25.00 price objective on the stock.

TEVA has been the topic of a number of other reports. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus price target of $24.50.

Teva Pharmaceutical Industries Trading Down 3.1%

Teva Pharmaceutical Industries stock traded down $0.57 during midday trading on Wednesday, reaching $17.58. The stock had a trading volume of 13,102,009 shares, compared to its average volume of 10,062,588. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a fifty day moving average of $15.49 and a 200 day moving average of $17.37. The firm has a market cap of $19.94 billion, a price-to-earnings ratio of -12.13, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.48 EPS. On average, analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently made changes to their positions in TEVA. Robeco Institutional Asset Management B.V. increased its position in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after acquiring an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $4,966,000. Asset Management One Co. Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after buying an additional 58,413 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 2,018.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after purchasing an additional 1,045,305 shares during the period. Finally, Capital Wealth Planning LLC grew its position in shares of Teva Pharmaceutical Industries by 8.8% in the fourth quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock valued at $5,435,000 after purchasing an additional 20,016 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.